Diagnosis of von Willebrand disease

Haemophilia

Volumn 5, Issue SUPPL. 2, 1999, Pages 50-56

  Ingerslev, J ^a   Gursel T ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

Bleeding disorder; Diagnosis; Family studies; Von Willebrand disease; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

CONFERENCE PAPER; HUMAN; PLASMA; PRIORITY JOURNAL; THROMBOCYTE; VON WILLEBRAND DISEASE;

EID: 0032796254     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1999.0050s2050.x     Document Type: Conference Paper

References (47)

1. von Willebrand EA. Hereditär pseudohemofili. Finska Läkarselskapets Handlingar 1926; 57: 87-112.
2. Lind SE. Prolonged bleeding time. Am J Med 1984; 77: 305-12.
3. Weippert-Kretschmer M, Witte M, Budde U, et al. A sensitive screening test for von Willebrand's disease. Semin Thromb Hemost 1995; 21 (Suppl. 2): 44-51.
4. Fressinaud E, Veyradier A, Truchaud F et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998; 91: 1325-31.
5. Carcao MD, Blanchette VS, Dean JA et al. The platelet function analyzer (FPA-100): a novel in-vitro system for evaluation of primary haemostasis in children. Br J Haematol 1998; 101: 70-3.
6. Ermens AA, de-Wild PJ, Vader HL, van der Graaf F. Four agglutination assays evaluated for measurement of von Willebrand factor (ristocetin cofactor activity). Clin Chem 1995; 41: 510-4.
7. Favaloro EJ, Koutts J. Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand's disease. Pathol 1997; 29: 385-91.
8. Short PE, Williams CE, Picken AM, Hill FGH. Factor VIII related antigen: an improved enzyme immunoassay. Med Lab Sci 1982; 39: 351-5.
9. Silveira AMV, Yamatoto T, Adamson L, Hessel B, Blombäck B. Application of an enzyme-linked immunosorbent assay (ELISA) to von Willebrand factor (vWF) and its derivatives. Thromb Res 1986; 43: 91-102.
10. Ingerslev J. A sensitive ELISA for von Willebrand factor (vWF:Ag). Scand J Clin Lab Invest 1987; 47: 143-9.
11. Murdock PJ, Woodhams BJ, Matthews KB, Pasi KJ, Goodall AH. von Willebrand factor activity detected in a monoclonal antibody-based ELISA. an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemostas 1997; 78: 1272-7.
12. Christophe O, Rouault C, Obert B, Pietu G, Meyer D, Girma J-P. A monoclonal antibody (B; 724): to von Willebrand factor recognizing an epitope within the A1 disulphide loop (Cys509-Cys695) discriminates between type 2A and type 2B von Willebrand disease. Br J Haematol 1995; 90: 195-203.
13. Ingerslev J, Bukh A, Møller NPH, Stenbjerg S, Zeuthen J. Applications of immunoperoxidase techniques inspecificity testing of monoclonal antibodies (MAbs) against von Willebrand factor (vWf). Clin Chim Acta 1988; 174: 65-82.
14. Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand antigen to collagen. Thromb Res 1986; 43: 303-111.
15. Favaloro EJ, Grispo L, Exner T, Koutts J. Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand's disease. Blood Coagul Fibrinolysis 1991; 2: 285-91.
16. Fischer BE, Thomas KB, Dorner F. von Willebrand factor: measuring its antigen or function?. Correlation between the level of antigen, activity, and multimeric size using various detection systems. Thromb Res 1998; 91: 39-43.
17. Williams SB, McKeown LP, Krutsch H, Hansmann K, Gralnick HR. Purification and characterization of human platelet von Willebrand factor. Br J Haematol 1994; 88: 582-91.
18. Gralnick HR, Rick ME, McKeown LP et al. Platelet von Willebrand factor: an important determinant of the bleeding time in type I von Willebrand's disease. Blood 1986; 68: 58-61.
19. Gralnick HR, Williams SB, McKeown LP et al. Platelet von Willebrand factor. Mayo Clin Proc 1991; 66: 634-40.
20. de Romeuf C, Mazurier C. Interest of a simple and fast method platelet von Willebrand factor characterization. Thromb Res 1996; 15: 287-98.
21. Ruggeri ZM, Zimmerman TS. Variant von Willebrand's disease: Characterization of two subtypes by analysis of multimeric composition of factor VIII-von Willebrand factor in plasma and platelets. J Clin Invest 1980; 65: 1318-25.
22. Miller MA, Palascak JE, Thompson MR, Martelo OJ. A modified SDS agarose gel method for determination of factor VIII von Willebrand factor multimers using commercially available reagents. Thromb Res 1985; 39: 777-80.
23. Bukh A, Ingerslev J, Stenbjerg S, Moller NPH. The multimeric structure of plasma F VIII. RAg studied by electroelution and immunoperoxidase detection. Thromb Res 1986; 43: 579-84.
24. Aihira M, Sawada Y, Ueno K et al. Visualization of von Willebrand factor multimers by immunoenzymatic stain using avidin-peroxidase complex. Thromb Haemostas 1986; 56: 263-7.
25. Raines G, Aumann H, Sykes S, Street A. Multimeric analysis of von Willebrand factor by molecular sieving electrophoresis in sodium dodecyl sulphate agarose gel. Thromb Res 1990; 60: 201-12.
26. Nordfang O, Ezban M, Dinesen B. Reactivity of factor VIII inhibitors in a micro ELISA for F VIII:CAg and in solid phase immunoisolation of VIII:CAg. Thromb Haemostas 1985; 53: 346-50.
27. Ingerslev J, Stenbjerg S. Enzyme linked immuno sorbent assay (ELISA) for the measurement of factor VIII coagulant antigen (CAg) using haemophilic antibodies. Br J Haematol 1986; 62: 325-32.
28. Hellstern P, Miyashita C, Köhler M et al. Measurement of factor VIII procoagulant antigen in normal subjects and in haemophilia A patients by an immunoradiometric assay and by an enzyme-linked immunosorbent assay. Haemostas 1987; 17: 173-81.
29. Scheiber J-D, Gritsch H, Lang H, Schoppmann A, Turecek PL. A new F VIII antigen assay serving as a tool for characterization of quality parameters in plasmaderived and recombinant factor VIII concentrates (Abstr). Haemophilia 1998; 4: 282. (Abstr 503).
30. Christiansen K, Ingerslev J. Development of polyclonal rabbit antibodies against human factor VIII for immunological studies. Haemophilia 1998; 4: 279 (Abstr 494).
31. Nishino M, Girma J-P, Rothschild C, Fressinaud E, Meyer D. New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989; 74: 1591-9.
32. Mazurier C, Dieval J, Jorieux S, Delobel J, Goudemand J. A new vWF defect in a patient with F VIII deficiency but with a normal level and multimeric patterns of both plasma and platelet vWF. Blood 1990; 75: 20-6.
33. Peerlink K, Eikenboom JC, Ploos van Amstel HK et al. A patient with von Willebrand's disease characterized by a compoundheterozygosity for a substitution of Arg854 by Gln in the putative factor-VIII-binding domain of von Willebrand factor (vWF) on one allele and very low levels of mRNA from the second allele. Br J Haematol 1992; 80: 358-63.
34. Schneppenheim R, Budde U, Krey S et al. Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von Willebrand disease type 1. Thromb Haemost 1996; 76: 598-602.
35. Mazurier C, Meyer D. Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease-results on an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemostas 1996; 76: 270-4.
36. Sadler E. A revised classification of von Willebrand disease. Thromb Haemostas 1994; 71: 520-5.
37. Blombäck M, Eneroth P, Andersson O, Anvret M. On laboratory problems in diagnosing mild von Willebrand's disease. Am J Haematol 1992; 40: 117-20.
38. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69: 454-9.
39. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand's disease. Blood 1987; 69: 1691-5.
40. Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in schoolchildren: a multiethnic study. J Pediatr 1993; 123: 893-8.
41. Rodeghiero F, Castaman G, Tosetto A. von Willebrand factor antigen is less sensitive than ristocetin cofactor for the diagnosis of type 1 von Willebrand disease-results based on an epidemiological investigation. Thromb Haemost 1990; 64: 349-52.
42. Vischer U, Ingerslev J, Wollheim C et al. Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWF:AgII) levels. Thromb Haemostas 1997; 77: 387-93.
43. de Romeuf C, Mazurier C. Comparison between von Willebrand factor (vWF) and vWF antigen II in normal individuals and patients with von Willebrand disease. Thromb Haemost 1998; 80: 37-41.
44. McCarroll DR, Ruggeri ZM, Montgomery RR. Correlation between circulating levels of von Willebrand's antigen II and vWF. Discrimination between type I and type II von Willebrand's disease. J Lab Clin Med 1984; 103: 704-11.
45. Vischer U, Emeis JJ, Bilo HJG, Stehower CDA, Thomsen C, Rasmussen O, Hermansen K, Wolheim CB, Ingerslev J. von Willebrand factor (vWF) as a plasma marker of endothelial activation in diabetes: Improved reliability with parallel determination of the vWF propeptide (vWF:AgII). Thromb Haemostas 1998; 80: 1002-7.
46. Zhang ZP, Falk G, Blombäck M, Egberg N, Anvret M. A single cytosine deletion in exon 18 of the von Willebrand factor gene is the most common mutation in Swedish vWD type III patients. Hum Mol Genet 1992; 1: 767-8.
47. Schneppenheim R, Krey S, Bergmann F et al. Genetic heterogeneity of severe von Willebrand's disease type III in the German population. Hum Genet 1994; 94: 640-52.